Business Wire

One in Five Businesses Have Paid or Would Pay a Ransom for Their Data, Finds Thales

Share

New research from Thales has found that malware, ransomware and phishing continues to plague global organisations. In fact, one in five (21%) have experienced a ransomware attack in the last year; with 43% of those experiencing a significant impact on operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005016/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

First seen in the late 1980’s, with the PC Cyborg Virus, the frequency and impact of ransomware attacks has now accelerated due to the rise of cryptocurrency as the preferred ransomware payment method. In fact, the 2022 Thales Data Threat Report, conducted by 451 Research, part of S&P Global Market Intelligence, including more than 2,700 IT decision-makers worldwide, found a fifth (22%) of organisations have admitted that they have paid or would pay a ransom for their data. Despite this, 41% of respondents said they had no plans to change security spending, even with greater ransomware impacts.

Additionally, less than half of respondents (48%) have implemented a formal ransomware plan. Healthcare was the most prepared at 57% with a formal ransomware plan; energy the least at 44%. Despite both sectors experiencing significant breaches over the past twelve months.

Data Visibility is a Challenge

As more companies adopt multicloud strategies and hybrid work remains the norm, IT leaders continue to be challenged by the sprawl of data across their organizations and find it more difficult to locate all of their data. Just over half (56%) of IT leaders were very confident or had complete knowledge of where their data was being stored, down from 64% the previous year1, and only a quarter (25%) stated they were able to classify all their data.

Threats & Compliance Challenges

Throughout 2021, security incidents remained high, with almost a third (29%) of businesses experiencing a breach in the past 12 months. Additionally, almost half (43%) of IT Leaders admitted to having failed a compliance audit.

Globally, IT leaders ranked malware (56%), ransomware (53%) and phishing (40%) as the leading source of security attacks. Managing these risks is an ongoing challenge, with almost half (45%) of IT leaders reporting an increase in the volume, severity and/or scope of cyberattacks in the past 12 months.

The Cloud is Increasing Complexity & Risk

Cloud adoption is increasing with more than a third (34%) of respondents saying they used more than 50 Software as a Service (SaaS) apps and 16% used more than 100 apps. However, 51% of IT leaders agreed that it is more complex to manage privacy and data protection regulations in a cloud environment than in on-premises networks within their organization, up from 46% last year.

The 2022 Data Threat Report also revealed significant momentum amongst businesses to store data in the cloud, with 32% of respondents stating that around halfi of their workloads and data resides in external clouds, and a quarter (23%) reporting more than 60%. However, 44% reported that they had experienced a breach or failed an audit in their cloud environments.

Additionally, the use of encryption to protect sensitive data is low, with only half of respondents (50%) disclosing that more than 40% of their sensitive data has been encrypted, and a fifth (22%) stating more than 60%. Representing a significant ongoing risk for businesses.

Remote Work Worries

Another full year of remote working demonstrated that navigating security risks is proving a significant challenge for businesses. Worryingly, the majority of businesses (79%) are still concerned about the security risks and threats that posed by remote working. Only half of IT leaders (55%) reported to have implemented multi factor authentication (MFA), a figure unchanged from the previous year2.

Threats on the Horizon

However, the report also showed that IT leaders have significant diversity of spending technology priorities – suggesting they are serious about tackling complex threat environments. A quarter (26%) stated that broad cloud security toolsets are the greatest future spending priority. Additionally, a similar number of IT leaders (25%) stated they were prioritising key management, with Zero Trust3 an important strategy for 23%.

IT leaders are also increasingly aware of the future challenges on the horizon. Looking ahead, when asked to identify security threats from quantum computing, 52% said they were concerned with ‘tomorrow’s decryption of today’s data’, a concern that will likely be intensified by the increasing complexity of cloud environments.

Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales, comments: “As the pandemic continues to affect both our business and personal lives, any expectation of a ‘return’ to pre-pandemic conditions have faded. Whilst teams around the world have continued to face challenges in securing their data, our findings indicate that urgent action is needed by businesses to develop more robust cybersecurity strategies. The attack surface, as well as the asset management challenges, are only set to increase in the coming year, and it is vital that businesses deploy a robust security strategy based on discovery, protection and control.”

Thales and 451 Research will discuss the findings in more detail during a webinar on 31 March 2022. To join, please visit the registration page.

About the 2022 Thales Global Data Threat Report

The 2022 Thales Global Data Threat Report was based on a global 451 Research survey, fielded in January 2022, commissioned by Thales of more than 2,700 executives with responsibility for or influence over IT and data security. Respondents were from 17 countries: Australia, Brazil, Canada, France, Germany, Hong Kong, India, Japan, Mexico, Netherlands, New Zealand, Singapore, South Korea, Sweden, the United Arab Emirates, the United Kingdom, and the United States. Organisations represented a range of industries, with a primary emphasis on healthcare, financial services, retail, technology, and federal government. Job titles ranged from C-level executives including CEO, CFO, Chief Data Officer, CISO, Chief Data Scientist, and Chief Risk Officer, to SVP/VP, IT Administrator, Security Analyst, Security Engineer, and Systems Administrator. Respondents represented a broad range of organizational sizes, with the majority ranging from 500 to 10,000 employees.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

1 Compared with data from the Thales 2021 Data Threat Report, conducted in January - February 2021.
2 Compared with data from the Thales 2021 Data Threat Report, conducted in January - February 2021.
3 Zero Trust is a strategic approach to cybersecurity that secures an organization by eliminating implicit trust and continuously validating every stage of a digital interaction.

i Respondents selected between 41-60% of their workloads and data resides in external clouds

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Security
Marion Bonnet
marion.bonnet@thalesgroup.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom